The role of autocrine motility factor in tumor and tumor microenvironment

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 725-735

  Funasaka, Tatsuyoshi ^a   Raz, Avraham ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMF; Angiogenesis; Hypoxia; PGI; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOCRINE MOTILITY FACTOR; AUTOCRINE MOTILITY FACTOR ANTIBODY; AUTOCRINE MOTILITY FACTOR INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; E 4P; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; DRUG MECHANISM; GENE FUNCTION; HOMEOSTASIS; HUMAN; HYPOXIA; METASTASIS; MICROENVIRONMENT; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; TUMOR; TUMOR CELL;

AUTOCRINE MOTILITY FACTOR; CELL HYPOXIA; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36148967682     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9086-7     Document Type: Review

References (123)

1. Fidler, I. J., & Poste, G. (1985). The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Seminars in Oncology, 12, 207-221.
2. Schnipper, L. (1986). Clinical implications of tumor-cell heterogeneity. New England Journal of Medicine, 314, 1423-1431
3. Liotta, L. A., Thorgeirsson, U. P., & Garbisa, S. (1982). Role of collagenases in tumor cell invasion. Cancer and Metastasis Reviews, 1, 277-288.
4. Strauli, P., & Haemmerli, G. (1984). The role of cancer cell motility in invasion. Cancer and Metastasis Reviews, 3, 127-141.
5. Woolley, D. E. (1984). Collagenolytic mechanisms in tumor cell invasion. Cancer and Metastasis Reviews, 3, 361-372.
6. Erickson, C. A. (1990). Cell migration in the embryo and adult organism. Current Opinion in Cell Biology, 2, 67-74.
7. Lauffenburger, D. A., & Horwitz, A. F. (1996) Cell migration: a physically integrated molecular process. Cell, 84, 359-369.
8. Carr, I. (1983). Lymphatic metastasis. Cancer and Metastasis Reviews, 2, 307-317.
9. Carr, J., Dreher, B., & Carr, I. (1983). Lymphatic metastasis; lymphangiochemotherapy of mammary cancer: ascitic form of rat mammary adenocarcinoma 13762. Clinical and Experimental Metastasis, 1, 29-38.
10. Bouwens, L., Jacobs, R., Remels, L., & Wisse, E. (1988). Natural cytotoxicity of rat hepatic natural killer cells and macrophages against a syngeneic colon adenocarcinoma. Cancer Immunology and Immunotherapy, 27, 137-141.
11. Weiss, L., Orr, F. W., & Honn, K. V. (1989). Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clinial and Experimental Metastasis, 7, 127-167.
12. Crissman, J. D., Hatfield, J., Schaldenbrand, M., Sloane, B. F., Honn, K.V. (1985). Arrest and extravasation of B16 amelanotic melanoma in murine lungs. A light and electron microscopic study. Laboratory Investigation, 53, 470-478.
13. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1, 27-30.
14. Weidner, N. (1995). Intratumor microvessel density as a prognostic factor in cancer. American Journal of Pathology, 147, 9-19.
15. Stoker, M., & Gherardi, E. (1991). Regulation of cell movement: the motogenic cytokines. Biochimica Et Biophysica Acta, 1072, 81-102.
16. Lazar-Molnar, E., Hegyesi, H., Toth, S., & Falus, A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12, 547-554.
17. Baggetto, L. G. (1997). Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies. Journal of Bioenergetics and Biomembranes, 29, 401-413.
18. Kerbel, R. S. (1990). Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Advances in Cancer Research, 55, 87-132.
19. Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R., & Fidler, I. J. (1994). Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. American Journal of Pathology, 145, 365-374.
20. Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour-host interface. Nature, 411, 375-379.
21. Fidler, I. J. (2002). The organ microenvironment and cancer metastasis. Differentiation, 70, 498-505.
22. Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571-573.
23. Fidler, I. J., Ellis, L. M. (2004). Neoplastic angiogenesis-not all blood vessels are created equal. New England Journal of Medicine, 351, 215-216.
24. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68.
25. Nakajima, M., Morikawa, K., Fabra, A., Bucana, C. D., & Fidler, I. J. (1990). Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. Journal of the National Cancer Institute, 82, 1890-1898.
26. Gutman, M., Singh, R. K., Xie, K., Bucana, C. D., & Fidler, I. J. (1995). Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Research, 55, 2470-2475.
27. Aaronson, S. A. (1991). Growth factors and cancer. Science, 254, 1146-1153.
28. McCormick, B. A., & Zetter, B. R. (1992). interactions in angiogenesis and metastasis. Pharmacology and Therapeutics, 53, 239-260.
29. Rodeck, U., Melber, K., Kath, R., Menssen, H. D., Varello, M., Atkinson, B., et al. (1991). Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. Journal of Investigative Dermatology, 97, 20-26.
30. Nicolson, G. L. (1993). Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Experimental Cell Research, 204, 171-180.
31. Radinsky, R. (1993). Paracrine growth regulation of human colon carcinoma organ-specific metastasis. Cancer and Metastasis Reviews, 12, 345-361.
32. Wilson, J., & Balkwill, F. (2002). The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology, 12, 113-120.
33. Liotta, L. A., Mandler, R., Murano, G., Katz, D. A., Gordon, R. K., Chiang, P. K., et al. (1986). Tumor cell autocrine motility factor. Proceedings of the National Academy of Sciences of the United States of America, 83, 3302-3306.
34. Liotta, L. A., Rao, C. N., & Barsky, S. H. (1983). Tumor invasion and the extracellular matrix. Laboratory Investigation, 49, 636-649.
35. Turley, E. A. (1992). Molecular mechanisms of cell motility. Cancer and Metastasis Reviews, 11, 1-3.
36. Seiki, M. (2002). The cell surface: the stage for matrix metalloproteinase regulation of migration. Current Opinion in Cell Biology, 14, 624-632.
37. Gomm, S. A., Keevil, B. G., Thatcher, N., Hasleton, P. S., & Swindell, R. S. (1988). The value of tumour markers in lung cancer. British Journal of Cancer, 58, 797-804.
38. Baumann, M., Kappl, A., Lang, T., Brand, K., Siegfried, W., & Paterok, E. (1990). The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Investigation, 8, 351-356.
39. Filella, X., Molina, R., Jo, J., Mas, E., & Ballesta, A. M. (1991). Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumour Biology, 12, 360-367.
40. Tsutsumi, S., Hogan, V., Nabi, I. R., & Raz, A. (2003). Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Research, 63, 242-249.
41. Yanagawa, T., Watanabe, H., Takeuchi, T., Fujimoto, S., Kurihara, H., & Takagishi, K. (2004). Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-β. Laboratory Investigation, 84, 513-522.
42. Watanabe, H., Takehana, K., Date, M., Shinozaki, T., & Raz, A. (1996). Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Research, 56, 2960-2963.
43. Kim, J. W., & Dang, C. V. (2005). Multifaceted roles of glycolytic enzymes. Trends in Biochemical Sciences, 30, 142-150.
44. Beutler, E., West, C., Britton, H. A., Harris, J., & Forman, L. (1997). Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood, Cells, Molecules and Diseases, 23, 402-409.
45. Jeffery, C. J., Bahnson, B. J., Chien, W., Ringe, D., & Petsko, G. A. (2000). Crystal Structure of Rabbit Phosphoglucose Isomerase, A Glycolytic Enzyme that Moonlights as Neuroleukin, Autocrin Motility Factor, and Differentiation Mediator. Biochemistry, 39, 955-964.
46. Ravindranath, Y., Paglia, D. E., Warrier, I., Valentine, W., Nakatani, M., & Brockway, R. A. (1987). Glucose phosphate isomerase deficiency as a cause of hydrops fetalis. New England Journal of Medicine, 316, 258-261.
47. Matsumoto, I., Staub, A., Benoist, C., & Mathis, D. (1999). Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science, 286, 1732-1735.
48. Funasaka, T., Haga, A., Raz, A., & Nagase, H. (2001). Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochemical and Biophysical Research Communications, 285, 118-128.
49. Dang, C. V., & Semenza, G. L. (1999) Oncogenic alterations of metabolism. Trends in Biochemical Sciences, 24, 68-72.
50. Gurney, M. E., Apatoff, B. R., Spear, G. T., Baumel, M. J., Antel, J. P., Bania, M. B., et al. (1986). Neuroleukin: a lymphokine product of lectin-stimulated T cells. Science, 234, 574-581.
51. Xu, W., Seiter, K., Feldman, E., Ahmed, T., & Chiao, J. W. (1996). The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood, 87, 4502-4506.
52. Yakirevich, E., & Naot, Y. (2000). Cloning of a glucose phosphate isomerase/neuroleukin-like sperm antigen involved in sperm agglutination. Biology of Reproduction, 62, 1016-1023.
53. Cao, M. J., Osatomi, K., Matsuda, R., Ohkubo, M., Hara, K., & Ishihara, T. (2000). Purification of a novel serine proteinase inhibitor from the skeletal muscle of white croaker (Argyrosomus argentatus). Biochemical and Biophysical Research Communications, 272, 485-489.
54. Niinaka, Y., Paku, S., Haga, A., Watanabe, H., & Raz, A. (1998). Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Research, 58, 2667-2674.
55. Silletti, S., Watanabe, H., Hogan, V., Nabi, I. R., & Raz, A. (1991). Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Research, 51, 3507-3511.
56. Shimizu, K., Tani, M., Watanabe, H., Nagamachi, Y., Niinaka, Y., Shiroishi, T., et al. (1999). The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Letters, 456, 295-300.
57. Watanabe, H., Nabi, I. R., & Raz, A. (1991). The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells. Cancer Research, 51, 2699-2705.
58. Kohn, E. C., Liotta, L. A., & Schiffmann, E. (1990). Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells. Biochemical and Biophysical Research Communications, 166, 757-764.
59. Silletti, S., Timar, J., Honn, K. V., & Raz, A. (1994). Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants. Cancer Research, 54, 5752-5756.
60. Watanabe, H., Carmi, P., Hogan, V., Raz, T., Silletti, S., Nabi, I. R., et al. (1991). Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. Journal of Biological Chemistry, 266, 13442-13448.
61. Ohta, Y., Minato, H., Tanaka, Y., Go, T., Oda, M., & Watanabe, Y. (2000). Autocrine motility factor receptor expression associates with tumor progression in thymoma. International Journal of Oncology, 17, 259-264.
62. Takanami, I., Takeuchi, K., Watanabe, H., Yanagawa, T., Takagishi, K., & Raz, A. (2001). Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer. International Journal of Cancer, 95, 384-387.
63. Timar, J., Raso, E., Dome, B., Ladanyi, A., Banfalvi, T., Gilde, K., & Raz, A. (2002). Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clinical and Experimental Metastasis, 19, 225-232.
64. Nabi, I. R., Watanabe, H., & Raz, A. (1992). Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer and Metastasis Reviews, 11, 5-20.
65. Silletti, S., & Raz, A. (1996). Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Current Topics in Microbiology and Immunology, 213, 137-169.
66. Folkman, J., & Klagsbrun, M. (1987). Angiogenic factors. Science, 235, 442-447.
67. Risau, W., Sariola, H., Zerwes, H. G., Sasse, J., Ekblom, P., Kemler, R., & Doetschman, T. (1988). Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development, 102, 471-478.
68. Folkman, J., & Shing, Y. (1992). Angiogenesis. Journal of Biological Chemistry, 267, 10931-10934.
69. Liekens, S., De Clercq, E., & Neyts, J. (2001) Angiogenesis: regulators and clinical applications. Biochemical Pharmacology, 61, 253-270.
70. Zetter, B. R. (1998). Angiogenesis and tumor metastasis. Annual Review of Medicine, 49, 407-424.
71. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., et al. (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. Journal of National Cancer Institute, 84, 1875-1887.
72. Vermeulen, P. B., Gasparini, G., Fox, S. B., Colpaert, C., Marson, L. P., Gion, M., et al. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. European Journal of Cancer, 38, 1564-1579.
73. Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
74. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., et al. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Laboratory Investigation, 67, 519-528.
75. Shibuya, M. (1995). Role of VEGF-flt receptor system in normal and tumor angiogenesis. Advances in Cancer Research, 67, 281-316.
76. Ferrara, N. (2002). VEGF and the quest for tumour angiogenesis factors. Nature Review Cancer, 2, 795-803.
77. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., & Nuseir N. (1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature, 329, 630-632.
78. Frater-Schroder, M., Risau, W., Hallmann, R., Gautschi, P., & Bohlen, P. (1987). Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proceedings of the National Academy of Sciences of the United States of America, 84, 5277-5281.
79. Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith. J. M., Roche, N. S., Wakefield, L. M., et al. (1986). Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 83, 4167-4171.
80. Heimark, R. L., Twardzik, D. R., & Schwartz, S. M. (1986). Inhibition of endothelial regeneration by type-β transforming growth factor from platelets. Science, 233, 1078-1080.
81. Muller, G., Behrens, J., Nussbaumer, U., Bohlen, P., & Birchmeier, W. (1987). Inhibitory action of transforming growth factor β on endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 84, 5600-5604.
82. Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O., et al. (1994). Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. Journal of Biological Chemistry, 269, 6271-6274.
83. Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., & Sorg, C. (1994). Macrophages and angiogenesis. Journal of Leukocyte Biology, 55, 410-422.
84. Sankar, S., Mahooti-Brooks, N., Bensen, L., McCarthy, T. L., Centrella, M., & Madri, J. A. (1996). Modulation of transforming growth factor β receptor levels on microvascular endothelial cells during in vitro angiogenesis. Journal of Clinical Investigation, 97, 1436-1446.
85. May, L. T., Torcia, G., Cozzolino, F., Ray, A., Tatter, S. B., et al. (1989). Interleukin-6 gene expression in human endothelial cells: RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochemical and Biophysical Research Communications, 159, 991-998.
86. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983-985.
87. Connolly, D. T. (1991). Vascular permeability factor: a unique regulator of blood vessel function. Journal of Cellular Biochemistry, 47, 219-223.
88. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., et al. (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research, 55, 360-368.
89. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991.
90. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P., Risau, W., et al. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835-846.
91. Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-848.
92. Hatva, E., Kaipainen, A., Mentula, P., Jaaskelainen, J., Paetau, A., Haltia, M., et al. (1995). Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. American Journal of Pathology, 146, 368-378.
93. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Journal of Clinical Investigation, 95, 1789-1797.
94. Funasaka, T., Haga, A., Raz, A., & Nagase, H. (2002). Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. International Journal of Cancer, 101, 217-223.
95. Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., et al. (2000). Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene, 19, 2138-2146.
96. Soker, S., Kaefer, M., Johnson, M., Klagsbrun, M., Atala, A., & Freeman, M. R. (2001). Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. American Journal of Pathology, 159, 651-659.
97. Barleon, B., Siemeister, G., Martiny-Baron, G., Weindel, K., Herzog, C., & Marme, D. (1997). Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Research, 57, 5421-5425.
98. Semenza, G. L. (2000). HIF-1 and human disease: one highly involved factor. Genes and Development, 14, 1983-1991.
99. Harris, A. L. (2002). Hypoxia-a key regulatory factor in tumour growth. Nature Review Cancer, 2, 38-47.
100. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Review Cancer 3, 721-732.
101. Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America, 92, 5510-5514.
102. Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998). Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitinproteasome pathway. Proceedings of the National Academy of Sciences of the United States of America, 95, 7987-7992.
103. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999). Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. Journal of Biological Chemistry, 274, 6519-6525.
104. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
105. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., et al. (2001). HIF-1α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 292, 464-468.
106. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., et al. (2001). Targeting of HIF-1α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472.
107. Sivitz, W. I., Lund, D. D., Yorek, B., Grover-McKay, M., & Schmid, P. G. (1992). Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. American Journal of Physiology, 263, E562-E569.
108. Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry, 269, 23757-23763.
109. Daly, E. B., Wind, T., Jiang, X. M., Sun, L., & Hogg, P. J. (2004). Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochimica Et Biophysica Acta, 1691, 17-22.
110. Yoon, D. Y., Buchler, P., Saarikoski, S. T., Hines, O. J., Reber, H. A., & Hankinson, O. (2001). Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 288, 882-886.
111. Niizeki, H., Kobayashi, M., Horiuchi, I., Akakura, N., Chen, J., Wang, J., et al. (2002). Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. British Journal of Cancer, 86, 1914-1919.
112. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., et al. (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research, 63, 1138-1143.
113. Funasaka, T., Yanagawa, T., Hogan, V., & Raz, A. (2005). Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB Journal, 19, 1422-1430.
114. Shimizu, S., Eguchi, Y., Kamiike, W., Itoh, Y., Hasegawa, J., Yamabe, K., et al. (1996). Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Reseacrh, 56, 2161-2166.
115. Koukourakis, M. I. (2001). Tumour angiogenesis and response to radiotherapy. Anticancer Research, 21, 4285-4300.
116. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science, 295, 1526-1528.
117. Giatromanolaki, A., & Harris, A. L. (2001). Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Research, 21, 4317-4324.
118. Han, B. H., & Holtzman, D. M. (2000). BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. Journal of Neuroscience, 20, 5775-5781.
119. Jin, K. L., Mao, X. O., & Greenberg, D. A. (2000). Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proceedings of the National Academy of Sciences of the United States of America, 97, 10242-10247.
120. Haga, A., Funasaka, T., Niinaka, Y., Raz, A., & Nagase, H. (2003). Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. International Journal of Cancer, 107, 707-714.
121. Romagnoli, A., Oliverio, S., Evangelisti, C., Iannicola, C., Ippolito, G., & Piacentini, M. (2003). Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis. Biochemical and Biophysical Research Communications, 302, 448-453.
122. Silletti, S., & Raz, A. (1993). Autocrine motility factor is a growth factor. Biochemical and Biophysical Research Communications, 194, 446-457.
123. Tsutsumi, S., Yanagawa, T., Shimura, T., Fukumori, T., Hogan, V., Kuwano, H., et al. (2003). Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. Journal of Biological and Chemistry, 278, 32165-32172.